Stephens Consulting LLC Buys 2,318 Shares of Pfizer Inc. (NYSE:PFE)

Stephens Consulting LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 66.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,826 shares of the biopharmaceutical company’s stock after acquiring an additional 2,318 shares during the period. Stephens Consulting LLC’s holdings in Pfizer were worth $155,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of PFE. Wells Trecaso Financial Group LLC increased its position in shares of Pfizer by 2.5% during the 3rd quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company’s stock worth $416,000 after purchasing an additional 350 shares in the last quarter. Washington Trust Advisors Inc. increased its holdings in shares of Pfizer by 0.7% during the third quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company’s stock worth $1,424,000 after buying an additional 360 shares in the last quarter. PSI Advisors LLC raised its stake in shares of Pfizer by 1.4% in the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 385 shares during the last quarter. Western Pacific Wealth Management LP boosted its holdings in shares of Pfizer by 10.5% in the 3rd quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 386 shares in the last quarter. Finally, Waddell & Associates LLC increased its holdings in Pfizer by 1.6% during the 3rd quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company’s stock valued at $723,000 after purchasing an additional 388 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock opened at $26.23 on Tuesday. The firm has a market capitalization of $148.62 billion, a P/E ratio of 35.44, a PEG ratio of 0.66 and a beta of 0.64. The business has a 50-day moving average of $26.27 and a 200-day moving average of $27.85. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. On average, equities analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.56%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is 232.44%.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Sanford C. Bernstein began coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Finally, StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.